SMARCA4 is altered in 4.95% of malignant solid tumor patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 Deficient Expression and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 2 clinical trials for rhabdoid tumor, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 Deficient Expression and rhabdoid tumor as inclusion criteria, 2 are phase 1 (1 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 is altered in 0.52% of acute myeloid leukemia patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 is altered in 7.81% of bladder carcinoma patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 Deficient Expression and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCA4 is altered in 2.41% of breast carcinoma patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 Deficient Expression and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCA4 is altered in 9.86% of endometrial endometrioid adenocarcinoma patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 Deficient Expression and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 Deficient Expression and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for extrarenal rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and extrarenal rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 is altered in 3.9% of lymphoma patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 is altered in 3.46% of malignant central nervous system neoplasm patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 is altered in 8.99% of malignant ovarian clear cell tumor patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 Deficient Expression and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCA4 is altered in 4.35% of malignant ovarian endometrioid tumor patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 Deficient Expression and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for rhabdoid tumor of the kidney, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 Deficient Expression and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCA4 is altered in 7.81% of sarcomatoid carcinoma patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 Deficient Expression and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCA4 is altered in 1.71% of soft tissue sarcoma patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 Deficient Expression and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCA4 is altered in 0.83% of synovial sarcoma patients [4].

SMARCA4 Deficient Expression is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 Deficient Expression and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].